Explore
Antibody Fc Engineering: Towards Better Therapeutics
Tianlei Ying and Rui Gong
2018
0 Ungluers have
Faved this Work
Login to Fave
Monoclonal antibodies and Fc-fusion proteins used clinically are Fc-based therapeutics that grow fastest in the pharmaceutical industry. Since they both contain an Fc fragment, engineering of Fc fragments could be a platform for improving Fc-based drug efficacy. Fc engineering includes various aspects: stabilization of Fc; regulation of effector functions including antibody-dependent cell-mediated cytotoxicity, complement-dependent cytotoxicity; extension of serum half-life by modification of neonatal Fc receptor (FcRn) binding; monomerization or heterodimerization of Fc for design of new Fc formats. Currently, many new methods are being used in Fc engineering. Compared to traditional methods such as site mutagenesis on certain positions by amino acid replacement, new methods such as display-based technology can confer high throughput screening and obtain optimized variants relatively quickly, accelerating the drug development process. With the new methods, many new Fc variants were identified. On this Research Topic we are going to review the progress in current Fc engineering including the new engineering methods and the Fc variants or constructs they have produced, and the potential of these new Fcs in clinical use.
This book is included in DOAB.
Why read this book? Have your say.
You must be logged in to comment.
Rights Information
Are you the author or publisher of this work? If so, you can claim it as yours by registering as an Unglue.it rights holder.Downloads
This work has been downloaded 126 times via unglue.it ebook links.
- 47 - mobi (CC BY) at Unglue.it.
- 41 - epub (CC BY) at Unglue.it.
- 38 - pdf (CC BY) at Unglue.it.
Keywords
- effector function
- Fc engineering
- Fc receptor
- Fc-fusion protein
- heterodimeric Fc
- medicine
- Monoclonal antibody
- monomeric Fc
Links
DOI: 10.3389/978-2-88945-678-9Editions